Category: Regional

Genentech Updates on Breast Cancer Study

South San Francisco, CA  December 4, 2023 Press Release Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation Phase III (INAVO120) results shows that inavolisib in combination…